About City Therapeutics
Engineering the future of RNAi-based medicines
- Industry
- Biotechnology Research
- Company size
- 11-50 employees
- Company type
- Privately Held
Founded by pioneering executives and scientists in RNAi, City Therapeutics is advancing next-generation engineering of small interfering RNAs (siRNAs) – the “trigger” molecules that mediate RNAi – to improve and expand the reach of RNAi-based medicines. City’s mission is to build the leading next-generation RNAi therapeutics company, unlocking RNAi’s transformative potential to help patients with a wide range of diseases.
Business areas
- Biopharma
- Life Science
- Therapeutics
On LinkedIn
- Followers
- 9,943
- People linked to this company
- 68
People who list this company on LinkedIn, not a verified employee count. Figures reflect the saved company profile.
Funding raised
135,000,000 USD
Total reported by Crunchbase, in US dollars. This is funding raised, not company revenue or valuation.
Explore the company
Employer category
Other employer
Estimated from the company profile. This category has not been confirmed by the employer.